Related Experiment Video
Updated: Apr 18, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Analysis of Clinical Factors Impacting Imatinib Trough Concentrations in Chinese Patients With Gastrointestinal
Cui Tang1, Jinxing Huang1, Jiadan Yang1
1Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background:
Imatinib mesylate (IM) is the first-line treatment for gastrointestinal stromal tumors (GISTs) and significantly improves patient outcomes. However, high inter-patient variability in imatinib plasma exposure leads to variable drug response. This study aimed to conduct a retrospective study to clearly assess the factors affecting the steady-state trough concentration (Css) of imatinib in Chinese patients with GIST.
Methods:
This retrospective analysis enrolled Chinese patients diagnosed with GIST who were treated with IM at 400 mg/d and underwent therapeutic drug monitoring. The CSS of IM was analyzed for differences and correlations with body mass index (BMI), age, sex, and creatinine clearance rate (CCr).
Results:
IM Css exhibited wide interpatient variability in this Chinese GIST cohort (n = 181). In univariate analyses, patients with higher BMI exhibited significantly lower IM CSS values compared to those with normal BMI (p < 0.05). Similarly, higher CCr values were associated with reduced IM Css (p < 0.001). Subsequent multiple linear regression analysis, adjusting for age and BMI, confirmed CCr as an independent determinant of imatinib exposure (p < 0.05). No significant differences were found between female and male patients or between elderly and non-elderly patients.
Conclusion:
CCr is an independent predictor of reduced imatinib exposure in Chinese patients with GIST. BMI, while correlated with drug concentration in initial analysis, appears to function as a significant clinical correlate whose association is substantially mediated through CCr. This highlights the importance of monitoring drug levels in patients with renal impairment to optimize dosing.
